INTRODUCTION AND OBJECTIVES: Current AUA Best Practice Statement recommends antibiotic prophylaxis for cystoscopy with manipulation, including stent removal, although no level 1b trials explicitly address prophylaxis for stent removal. We sought to prospectively determine the efficacy of prophylactic antibiotics to prevent infectious complications after cystoscopic stent removal.
METHODS: Following IRB approval, subjects undergoing removal of ureteral stent placed during stone surgery were recruited at UC San Diego and Genesis Healthcare from July 2016 to October 2018. Co-variates included age, BMI, comorbidities, surgery type, stone composition, UTI history, bladder urine culture (UCx) at stone surgery, bladder UCx and post-void residual at time of stent removal. Subjects were recruited at time of stent removal and randomized to treatment (single dose 500mg oral Ciprofloxacin) or control group (nothing). Subjects with indwelling stents longer than 3 weeks were excluded. Telephone contact with subject was performed 14 days after stent removal to assess for UTI symptoms, antibiotic prescriptions, or ED visits. Primary outcome was UTI within 2 weeks of stent removaldefined by irritative void symptoms, fever or abdominal pain associated with clean catch culture >100k colonies/mL. RESULTS: To date, 65 subjects have been enrolled with 46 meeting final inclusion criteria for analysis (26 treatment, 20 control (Treatment n[22, Control n[19) , no subjects in either group reported fever, seeing a physician or an emergency department for urinary complaints, receiving additional antibiotics or being admitted for infection.
CONCLUSIONS: Initial data suggests antibiotic prophylaxis for cystoscopic removal of ureteral stents does not reduce infectious complication rate. Completion of the trial will help determine if the necessity of antibiotics during routine cystoscopic stent removal warrants AUA Best Practice Statement re-evaluation.
Source of Funding: None

PD42-09 EFFECTIVENESS OF DIFFERENT POSTOPERATIVE ANALGESICS IN THE MANAGEMENT OF ACUTE PAIN AFTER URETEROSCOPY
Nadeem Iqbal*, Hasan Aisha, Lahore, Pakistan; Umar Alam, Islamabad, Pakistan; Rahim Waqas, Tauqeer Fiaz, Zafar Nauman, bhatty Tanweer, Saeed Akhter, Lahore, Pakistan INTRODUCTION AND OBJECTIVES: Recently it has been noted that efforts have been made to implement non-opioid protocols for outpatient urologic surgery. Literature in recent past has demonstrated that ureteroscopy (URS) with stent placement is possible without using postoperative opioids for pain control and stent-related symptoms. In this study, we evaluated the feasibility of a non-opioid discharge protocol compared to standard opioid medications for postoperative pain following URS and stent placement over a 8 months period.
METHODS: Charts review of patients who underwent URS with stent placement was done over a 8-month period from February 2018 to October 2018 were retrospectively reviewed. Patients were discharged on paracetamol or diclofenac (NSAID) or tramadol (opioid) in groups 1,2 and 3 respectively. Patients having normal renal function and no evidence of current or prior opioid tolerance were included in the study. We noted the frequency of postoperative events including visits to the emergency room (ER) for stent-related symptoms, and need for prescription refills for these 3 groups. Postoperative pain intensity was measured by nurse in the recovery room and at 0, 6, 12, 24, 48, & 72 hours using the Verbal Intensity Pain Scale (VIPS).A mean pain score of less than 2 for each category of surgical procedures or analgesics group was defined as satisfactory pain control. Anova t test was applied to see for statistically significant difference in mean pain scores between these groups. RESULTS: Total of 120 patients underwent URS with double j stent placement: with 40 patients in each group. Eighty patients (of group 1 and 2) were not given opioids and were then discharged on opioid free pain killer. The mean pain score was >2 at 6 h postoperative in all three groups. However pain was satisfactorily controlled in 90%, 92.5% and 90% in the respective groups 1, 2 and 3 (p[0.09). Of those discharged without an opioid, 60 received paracetamol and and 20 received diclofenac as pain killer. It was noted that the different analgesics prescribed for postoperative pain management provided satisfactory pain control based on mean pain score obtained at different intervals during 3 days after the surgery. There was no difference in the percentage of patients who had postoperative visits to the ER for genitourinary-related concerns (3/40 patients receiving opioids and 7/80 patients without opioids; p[0.89). The number of additional pain killers need for refill was similar between the three groups (5/40 patients receiving opioids (12.5%) and 8/80 patients without opioids (10.%); p[0.19).
CONCLUSIONS: This study demonstrates the feasibility of a non-opioid postoperative protocol even in acute setting in recovery for those undergoing URS in carefully selected patients. Compared to patients receiving opioids, these patients receiving non-opioid therapies had similar pain scores in 3 days after surgery and similar pain killers refill requests. There should be such studies on other urologic procedure as well in future to look for Non-opioids and even NSAIDS free pain killers.
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PD42-10 EFFECTS OF SILICONE HYDROCOATED DOUBLE LOOP URETERAL STENT (DJ) ON SYMPTOMS AND QUALITY OF LIFE IN PATIENTS UNDERGOING F-URS FOR KIDNEY STONE: FINAL RESULTS OF A PROSPECTIVE RANDOMIZED MULTICENTRE CLINICAL STUDY
Oliver Wiseman*, Cambridge, United Kingdom; Julien Letendre, Montreal, Canada; Jonathan Cloutier, Quebec, Canada; Michel Daudon, Paris, France; Francois Kleinclauss, Besancon, France; Steeve Doizi, Olivier Traxer, Paris, France INTRODUCTION AND OBJECTIVES: Silicone was one of the first materials to be used for DJ ureteral stents. Due to its softness, it is purported to be associated with less patient discomfort. However, there are no clinical trials showing this. In this large multicenter prospective study, we compared the hydrocoated silicone stent (Coloplast ImajinÒ hydro) to Percuflex TM Plus stent (Boston Scientific) in terms of patient comfort after flexible ureteroscopy (FURS) for stone disease over a 5-week prospective follow-up.
METHODS: Between November 2013 and December 2017, 141 patients treated for unilateral renal stones from 5 to 25 mm by F-URS were randomized, following ethical committee approval in the respective centres, under a prospective, comparative, single blind, parallel groups protocol across 4 centres in France, UK and Canada. The primary endpoint was USSQ Body Pain Index recorded before DJ removal at D20. Secondary endpoints were USSQ scores at intermediate dates (D2, D7) and 2 weeks after stent withdrawal (D35), pain score, quality of life, adverse events, and encrustation. Exclusion criteria included pregnancy, active infection, chronic pain, urogenital tumor, presence of an implanted double J stent, treatment for BPH, prostatitis, or neuro/cognitive disease. Vol. 201, No. 4S, Supplement, Sunday, May 5, 2019 THE JOURNAL OF UROLOGY Ò e753
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